Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -107.9x - -119.2x | -113.6x |
| Selected Fwd P/E Multiple | -10.0x - -11.0x | -10.5x |
| Fair Value | $0.045 - $0.050 | $0.048 |
| Upside | -38.6% - -32.1% | -35.4% |
| Benchmarks | - | Full Ticker |
| Thermo Fisher Scientific Inc. | - | NYSE:TMO |
| Medpace Holdings, Inc. | - | NasdaqGS:MEDP |
| Quanterix Corporation | - | NasdaqGM:QTRX |
| Inotiv, Inc. | - | NasdaqCM:NOTV |
| Repligen Corporation | - | NasdaqGS:RGEN |
| Reflect Scientific, Inc. | - | OTCPK:RSCF |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| TMO | MEDP | QTRX | NOTV | RGEN | RSCF | |||
| NYSE:TMO | NasdaqGS:MEDP | NasdaqGM:QTRX | NasdaqCM:NOTV | NasdaqGS:RGEN | OTCPK:RSCF | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 11.4% | 32.2% | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | -6.4% | 30.6% | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 8.0% | 33.3% | -48.5% | -22.7% | -197.6% | 90.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 16.6% | 16.3% | -48.4% | -23.2% | 12.8% | 3.6% | ||
| Prior Fiscal Year | 14.0% | 15.0% | -23.2% | -18.4% | 5.6% | 4.4% | ||
| Latest Fiscal Year | 14.8% | 19.2% | -28.0% | -22.1% | -4.0% | -42.5% | ||
| Latest Twelve Months | 15.2% | 19.3% | -35.3% | -18.2% | -3.5% | -1.7% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 17.6x | 18.4x | -0.7x | 18.3x | 63.0x | NA | ||
| Price / LTM Sales | 3.8x | 4.3x | 2.0x | 0.1x | 11.0x | 3.2x | ||
| LTM P/E Ratio | 24.9x | 22.2x | -5.7x | -0.8x | -311.6x | -188.9x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -311.6x | -0.8x | 24.9x | |||||
| Historical LTM P/E Ratio | -29.4x | 10.2x | 247.8x | |||||
| Selected P/E Multiple | -107.9x | -113.6x | -119.2x | |||||
| (x) LTM Net Income | (0) | (0) | (0) | |||||
| (=) Equity Value | 3 | 3 | 4 | |||||
| (/) Shares Outstanding | 85.7 | 85.7 | 85.7 | |||||
| Implied Value Range | 0.04 | 0.04 | 0.04 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.04 | 0.04 | 0.04 | 0.07 | ||||
| Upside / (Downside) | -49.7% | -47.1% | -44.4% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | TMO | MEDP | QTRX | NOTV | RGEN | RSCF | |
| Value of Common Equity | 162,069 | 9,240 | 271 | 72 | 7,162 | 6 | |
| (/) Shares Outstanding | 377.5 | 28.7 | 38.8 | 34.4 | 56.2 | 85.7 | |
| Implied Stock Price | 429.33 | 321.50 | 6.98 | 2.09 | 127.47 | 0.07 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 429.33 | 321.50 | 6.98 | 2.09 | 127.47 | 0.07 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |